Altimmune, Inc. (ALT)
Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class Action - ALT
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").
FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / July 4, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").
Shareholders that lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class Action - ALT
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders that lost money on Altimmune, Inc. (ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. NASDAQ: ALT focuses on developing peptide-based therapeutics for obesity and chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Their top candidate is a GLP-1/glucagon agonist called pemvidutide.
Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
